Elisabeth Pharmacon Research and Development Center (Q9634): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in 1 language: translated_label)
(‎Removed claim: summary (P836): The project is focused on the development of the existing research, development and innovation centre of the company, which is used to develop innovative procedures of medical DNA diagnostics of infectious and genetically conditioned diseases. The aim of the project is to strengthen current development and innovation capacities, focusing on the latest trends in our field, including new generation sequencing methods. The project focuses on the...)
Property / summary
The project is focused on the development of the existing research, development and innovation centre of the company, which is used to develop innovative procedures of medical DNA diagnostics of infectious and genetically conditioned diseases. The aim of the project is to strengthen current development and innovation capacities, focusing on the latest trends in our field, including new generation sequencing methods. The project focuses on the development of innovative diagnostic procedures and sets. (English)
 
Property / summary: The project is focused on the development of the existing research, development and innovation centre of the company, which is used to develop innovative procedures of medical DNA diagnostics of infectious and genetically conditioned diseases. The aim of the project is to strengthen current development and innovation capacities, focusing on the latest trends in our field, including new generation sequencing methods. The project focuses on the development of innovative diagnostic procedures and sets. (English) / rank
Normal rank
 

Revision as of 14:52, 22 October 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Elisabeth Pharmacon Research and Development Center
Project in Czech Republic financed by DG Regio

    Statements

    country
    Czechia
    0 references
    EU contribution
    6,742,616.0 Czech koruna
    0 references
    269,704.64 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    13,485,232.0 Czech koruna
    0 references
    539,409.28 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    50 percent
    0 references
    start time
    26 June 2015
    0 references
    end time
    25 June 2018
    0 references
    expected end time
    25 June 2018
    0 references
    beneficiary name (string)
    ELISABETH  PHARMACON, spol. s r.o.
    0 references
    coordinate location

    49°11'55.75"N, 16°38'29.22"E
    0 references
    postal code
    61500
    0 references
    summary
    Projekt je zaměřen na rozvoj stávajícího výzkumného, vývojového a inovačního centra společnosti, které slouží k vývoji inovativních postupů lékařské DNA diagnostiky infekčních a geneticky podmíněných chorob. Cílem projektu je posílení současných vývojových a inovačních kapacit, zaměřené na nejnovější trendy v našem oboru včetně metod sekvenování nové generace. Projekt se soustřeďuje na vývoj inovativních diagnostických postupů a souprav. (Czech)
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/15_002/0000699
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q9634&oldid=6594166"